Quantification of Tumor DNA in Serum and Vascular Invasion of Human Hepatocellular Carcinoma

Objectives: Hepatocellular carcinoma (HCC) is one of the common cancers worldwide. Accurate diagnosis of tumor progression is critical for the appropriate management of HCC. Here, we established a sensitive assay to detect and quantify tumor-derived DNA in the serum of HCC patients. Methods: Aberrant methylation of the APC gene was quantified in 23 HCC patients and 8 healthy volunteers using 100 µl of serum. For sensitive detection and accurate quantification of tumor DNA, we combined seminested polymerase chain reaction (PCR) with TaqMan PCR, which could amplify the APC gene regardless of the methylation status and detect the methylated and unmethylated sequences separately. The ratio of methylated to unmethylated sequences was quantified. Results: The methylated APC gene was detected in all HCC patients examined, but no healthy volunteers showed amplification of methylated sequences in serum. HCC patients with portal vein thrombosis showed a significantly higher methylated to unmethylated APC gene ratio in serum than those without portal vein thrombosis (p = 0.0029). Conclusions: Considering the strong association between the ratio of the methylated to unmethylated APC sequences in serum and the presence of portal vein thrombosis, methylation status of APC sequences could be a promising marker for improving HCC management.

[1]  M. Kudo,et al.  Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma , 2012, Hepatology.

[2]  J. Belghiti,et al.  Liver Resection and Transplantation in Hepatocellular Carcinoma , 2012, Liver Cancer.

[3]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[4]  D. Y. Kim,et al.  Epidemiology and Surveillance of Hepatocellular Carcinoma , 2012, Liver Cancer.

[5]  R. Lencioni Chemoembolization in Patients with Hepatocellular Carcinoma , 2012, Liver Cancer.

[6]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[7]  N. Nishida,et al.  Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma: A Systematic Review , 2011, Current genomics.

[8]  N. Iizuka,et al.  Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[9]  N. Nishida Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis. , 2010, Histology and histopathology.

[10]  William M. Lee,et al.  Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.

[11]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[12]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[13]  C. Boland,et al.  Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma , 2008, Hepatology.

[14]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[15]  C. Boland,et al.  Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. , 2007, Cancer research.

[16]  W. Tsai,et al.  Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA , 2007, Clinical Cancer Research.

[17]  W. Lau,et al.  Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[19]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[20]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[21]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[22]  Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. , 1993, Cancer research.